What if you invested $1000 in NVO on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Novo Nordisk A/S has delivered an average annual return of 22.1%. The stock peaked in 2010 with a massive +74.6% gain, while investors faced a downturn in 2025 (-40.9%). Overall, the stock finished in the green 15 times out of 20 years.
Avg Return
+22.1%
Win Rate
75%
15W - 5L
Best
+74.6%
2010
Worst
-40.9%
2025
Performance Consistency
About Novo Nordisk A/S
Visit Website ↗Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, built upon its heritage in diabetes.
Key Business Segments
Diabetes and Obesity care
Insulin, GLP-1 analogs (Ozempic, Wegovy).
Rare Diseases
Hemophilia, growth disorders, and hormone replacement therapy.
Key Innovations
- ✓Semaglutide (Ozempic/Wegovy/Rybelsus)
- ✓Modern insulins
Historical Milestones
Nordisk Insulinlaboratorium founded.
Merger of Nordisk Gentofte and Novo Industri to form Novo Nordisk.
Wegovy approved by FDA for weight management.